[1] Chesbrough, H. (2003). Open Innovation. Cambridge. MA: Harvard University Press.
[2] OECD. (2006). Open innovation in global networks. Organization for Economic Cooperation and Development, Policy document.
[3] Boyer, R. (2004). New growth regimes, but still institutional diversity. Socio-Economic Review, 2(1), 1-32.
[4] Teece, D. (1988). Technological Change and the Nature of the Firm in Technical Change and Economic Theory. Edited by Dosi, G., Freeman, C., Nelson, R., Silveiberg, G., and Soete, L. Francis Printer, London.
[5] Hollingsworth, J. R. (1991). The logic of coordinating American manufacturing sectors. Governance of the American economy, 5, 35.
[6] Herstad, S. J., Bloch, C., Ebersberger, B., & Van De Velde, E. (2010). National innovation policy and global open innovation: exploring balances, tradeoffs and complementarities. Science and Public Policy, 37(2), 113-124.
[7] Rothwell, R. (1994). Towards the fifth-generation innovation process. International marketing review, 11(1), 7-31.
[8] Marinova, D., & Phillimore, J. (2003). Models of innovation. In Shavinina, V. (Ed.). International handbook on innovation. Amsterdam: Elserver.
[9] Tidd, J. (2006). A review of innovation models. Imperial College London, discussion paper 1.
[10] Berkhout, A. J., Hartmann, D., Van Der Duin, P., & Ortt, R. (2006). Innovating the innovation process. International journal of technology management, 34(3-4), 390-404.
[11] Boehm, G., & Fredericks, L. J. (2010). Strategic innovation management in global industry networks: The TFT LCD Industry. Asian Journal of Business Management, 2(4), 110-120.
[12] Barbieri, J. C., & Álvares, A. C. T. (2016). Sixth generation innovation model: description of a success model. RAI Revista de Administração e Inovação, 13(2), 116-127.
[13] Chesbrough, H. W. (2006). Open innovation: The new imperative for creating and profiting from technology. Harvard Business Press.
[14] Raja, B. H. (2015). Open innovation in pharmaceutical industry: A case study of Eli Lilly. M.Sc. Thesis in KTH University, Sweden.
[15] Bianchi, M., Cavaliere, A., Chiaroni, D., Frattini, F., & Chiesa, V. (2011). Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis. Technovation, 31(1), 22-33.
[16] Zhang, J. (2014). Global drug discovery outsourcing market gaining momentum. Life science leader.
[17] Uddin, M. B., & Akhter, B. (2011). Strategic alliance and competitiveness: theoretical framework. Researchers World, 2(1), 43-54.
[18] Festel, G., & De Cleyn, S. H. (2011). R&D Spin-outs in the Pharmaceutical Industry. Journal of Business Chemistry, 8(3), 101-113.
[19] Harwood, R. (2016). The Open Innovation Methods Matrix. 100 open, Accessed through: https://www.100open.com/the-open-innovation-methods-matrix-part-1/
[20] Van der Zee, F., Rehfeld, D., & Hamza, C. (2015). Open innovation in industry, including 3D printing. Disponible en ligne sous http://www. europarl. europa. eu/RegData/etudes/STUD/2015/563445/IPOL_STU.
[21] Chesbrough, H., Vanhaverbeke, W., Bakici, T., & Lopez-Vega, H. (2011). Open innovation and public policy in Europe. Barcelona, Spain: ESADE Business School, Science Business Innovation Board.
[22] Moedas, C. (2016). Open Innovation, Open Science and Open to the World–A Vision for Europe. Luxembourg: Publications Office of the European Union.
[23] De Jong, J. P., Kalvet, T., & Vanhaverbeke, W. (2010). Exploring a theoretical framework to structure the public policy implications of open innovation. Technology Analysis & Strategic Management, 22(8), 877-896.
[24] Naghizadeh, R. (2017). The Pattern of Cooperation Between Small Knowledge-Based Firms and Industrial and Economic Firms; by Guaranteed-Buys Method. Journal of Science and Technology Policy, 9(2), 67-81. {In Persian}.
[25] Yun, J. J., Won, D., Hwang, B., Kang, J., & Kim, D. (2015). Analysing and simulating the effects of open innovation policies: Application of the results to Cambodia. Science and Public Policy, 42(6), 743-760.
[26] Salim, A., Razavi, M. R., & Afshari-Mofrad, M. (2017). Foreign direct investment and technology spillover in Iran: The role of technological capabilities of subsidiaries. Technological Forecasting and Social Change, 122, 207-214.
[27] Salim, A., Razavi, M. R., Radfar, R., Ghaffari, F., & Afshari-Mofrad, M. (2018). Assessing the Effects of Foreign Direct Investment on Technology Spillovers to Subsidiaries in Iran. Journal of Science & Technology Policy, 10(2), 47-55. {In Persian}.
[28] Ghazinoory, S., & Shakeri, R. (2017). Integrating industrial, trade and technology policies in Iran’s biopharmaceutical industry. Institute for Trade Studies and Research, Tehran. {In Persian}.
[29] Afshari-Mofrad, M., & Salim, A. (2019). Iranian firms in biopharmaceutical value chain: where to go now?. Journal of Science and Technology Policy Management.
)
